Pulmonology

In a recent meta-analysis, researchers sought to examine the safety of procalcitonin-guided antibiotic therapy among patients with acute respiratory infections.

Researchers determined the feasibility and benefits of switching from PDE5i therapy to riociguat in patients with PAH who fail PDE5i therapy.

The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.

Few studies have compared the effects of once-daily triple therapy with twice-daily dual therapy for COPD. In a recent study, researchers more thoroughly compared these treatments.

In the Global Burden of Diseases, Injuries, and Risk Factors Study 2015, researchers aimed to estimate the global prevalence of lower respiratory infections and associated rates of mortality across all age...

The aim of the Global Burden of Disease Study was to estimate the worldwide prevalence of and deaths associated with chronic obstructive pulmonary disease and asthma.

In a recent study, researchers investigated the effects of pulmonary hypertension on mortality rates among COPD patients undergoing single and bilateral lung transplant.

The US Food and Drug Administration has expanded the approval of a drug used to treat cystic fibrosis.

A recent study sought to determine the prevalence of antibiotic prescribing for nonbacterial acute upper respiratory tract infections in elderly patients and to better understand factors associated with...

Pulmonary arterial hypertension can be associated with exposure to certain drugs, such as anorectic agents or selective serotonin reuptake inhibitors.